Active Ingredient History
Deferiprone (trade name Ferriprox) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is an orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. All the adverse effects of deferiprone are considered reversible, controllable and manageable. These include agranulocytosis with frequency of about 0.6%, neutropenia 6%, musculoskeletal and joint pains 15%, gastrointestinal complains 6% and zinc deficiency 1%. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Iron Overload (approved 2011)
Thalassemia (approved 2011)
Acute Kidney Injury (Phase 3)
Alzheimer Disease (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 2/Phase 3)
Anemia (Phase 4)
Anemia, Sickle Cell (Phase 4)
Ascorbic Acid (Phase 2/Phase 3)
beta-Thalassemia (Phase 4)
Blood Platelet Disorders (Phase 2/Phase 3)
Blood Transfusion (Phase 2)
Cardiomyopathies (Phase 4)
Cardiovascular Diseases (Phase 2)
Cognitive Dysfunction (Phase 2)
Dementia (Phase 2)
Diabetes Mellitus (Phase 2/Phase 3)
Friedreich Ataxia (Phase 2)
Healthy Volunteers (Phase 1)
Hearing Loss, Sensorineural (Phase 2/Phase 3)
Heart (Phase 4)
Heart Diseases (Phase 2)
Hemochromatosis (Phase 3)
Hemosiderosis (Phase 4)
HIV Infections (Phase 1)
Iron (Early Phase 1)
Iron Metabolism Disorders (Phase 2/Phase 3)
Iron Overload (Phase 4)
Kidney Diseases (Phase 2)
Kidney Failure, Chronic (Phase 4)
Liver Diseases (Phase 4)
Myelodysplastic Syndromes (Phase 2)
Myocardial Infarction (Phase 1)
Neurodegenerative Diseases (Phase 2)
Optic Atrophy (Phase 2/Phase 3)
Parkinson Disease (Phase 2/Phase 3)
Peptic Ulcer (Phase 2/Phase 3)
Stroke (Phase 2)
Subarachnoid Hemorrhage (Phase 2)
Thalassemia (Phase 2/Phase 3)
Therapeutic Equivalency (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue